Blais, Joseph Edgar

default-profile
Post-doctoral Fellow

Division of Epidemiology and Biostatistics

  • BScPharm, PhD, BCPS
Biography

Dr Joseph Blais joined the School of Public Health in 2022 after obtaining his PhD in Pharmacoepidemiology with the Department of Pharmacology and Pharmacy at the University of Hong Kong. His research interests include using electronic health records to assess the comparative effectiveness and safety of drugs, drug utilization research and evidence-based medicine. Dr Blais’ primary research focus is to enhance approaches to case-based surveillance of antimicrobial resistant infections using electronic health records.

After studying pharmacy at the University of Alberta, Dr Blais completed a pharmacy practice residency with Alberta Health Services Edmonton Zone. He then worked as Clinical Pharmacist at the University of Alberta Hospital. He is a registered pharmacist with the Pharmacy and Poisons Board of Hong Kong and the Alberta College of Pharmacy, Canada, and board certified in pharmacotherapy (BCPS) with the Board of Pharmacy Specialties, USA.
Selected Publications
  1. Blais JE, Wei Y, Knapp M, Wong ICK, Wei L, Chan EW. Trends in PCSK9 inhibitor utilization in the United States, Europe, and other countries: An analysis of international sales data. Am Heart J. 2022;248:13-20. doi: https://doi.org/10.1016/j.ahj.2022.02.008.
  2. Brauer R, Alfageh B, Blais JE, Chan EW, Chui CSL, Hayes JF, Man KKC, Lau WCY, Yan VKC, Beykloo MY, Wang Z, Wei L, Wong ICK. Psychotropic medicine consumption in 65 countries and regions, 2008–19: a longitudinal study. Lancet Psychiatry. 2021;8(12):1071-82. doi: https://doi.org/10.1016/S2215-0366(21)00292-3.
  3. Blais JE, Wei Y, Yap KKW, Alwafi H, Ma T-T, Brauer R, Lau WCY, Man KKC, Siu CW, Tan KC, Wong ICK, Wei L, Chan EW. Trends in lipid-modifying agent use in 83 countries. Atherosclerosis. 2021;328:44-51. doi: https://doi.org/10.1016/j.atherosclerosis.2021.05.016.
  4. Blais JE, Tong GKY, Pathadka S, Mok M, Wong ICK, Chan EW. Comparative efficacy and safety of statin and fibrate monotherapy: a systematic review and meta-analysis of head-to-head randomized controlled trials. PLoS One. 2021;16(2):e0246480. doi: https://doi.org/10.1371/journal.pone.0246480.
  5. Zhao J, Blais JE, Chui CSL, Suh IH, Chen EYH, Seto WK, Mok MT, Yan VKC, Lau WCY, Wong ICK, Chan EW. Association between nonvitamin K antagonist oral anticoagulants or warfarin and liver injury: a cohort study. Am J Gastroenterol. 2020;115(9):1513-24. doi: https://doi.org/10.14309/ajg.0000000000000678.
  6. Li X, Blais JE, Wong ICK, Tam AWY, Cowling BJ, Hung IFN, Chan EWY. Population-based estimates of the burden of pneumonia hospitalizations in Hong Kong, 2011-2015. Eur J Clin Microbiol Infect Dis. 2019;38(3):553-61. doi: https://doi.org/10.1007/s10096-018-03459-x.
  7. Blais JE, Chan EW, Law SWY, Mok MT, Huang D, Wong ICK, Siu C-W. Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004–2015. Atherosclerosis. 2019;280:174-82. doi: https://doi.org/10.1016/j.atherosclerosis.2018.11.015.
Back